학술논문

Serum levels of fetuin-A as a novel biomarker for disease activity in patients with Takayasu arteritis and granulomatous polyangiitis
Document Type
Original Paper
Source
Clinical Rheumatology: Journal of the International League of Associations for Rheumatology. 41(4):1169-1176
Subject
α2-Heremans-Schmid Glycoprotein/Fetuin-A (AHSG)
Granulamatous polyangiitis
Takayasu arteritis
Vascular calcification
Language
English
ISSN
0770-3198
1434-9949
Abstract
Objective: The aim of the present study was to investigate serum fetuin-A (Fet-A) levels in patients with Takayasu arteritis (TA) and granulomatous polyangiitis (GPA) and to analyze the relationship between serum Fet-A levels and disease activity scores.Method: Thirty-two TA and 28 GPA patients presented to the rheumatology clinic at Gazi University and met the criteria of American College of Rheumatology 1990 and 2012 International Chapell Hill meeting, respectively, and 20 healthy control subjects were included in the present study. We collected data on serum C-reactive protein (CRP), albumin, calcium, and phosphate levels as well as erythrocyte sedimentation rates. Calcification risk index (CRI) was calculated for each patient. The Birmingham Vasculitis Activity Score (BVAS) and Indian Takayasu Clinical Activity Score (ITAS), were used to assess disease activity in GPA and TA patients respectively.Results: Serum Fet-A levels were significantly lower in the overall vasculitis group compared to control group (p = 0.015). In subgroup analysis, Fet-A levels were significantly lower in those with active disease, compared to control group (p = 0.001, for active TA (n = 18) and GPA (n = 17), respectively). However, there was no significant difference in serum Fet-A levels in inactive cases versus control subjects (p = 0.061, for inactive TA (n = 14) and GPA (n = 11), respectively). Serum Fet-A levels negatively correlated with BVAS (r =  − 0.675) and ITAS scores (r =  − 0.385), as well as with CRP and CRI.Conclusion: Our results suggest that serum Fet-A level could be a novel biomarker for assessment of activity status in patients with GPA or TA.[Table Removed]